Post Reply
321-340 of 10899
It's time for company to activate share buy-back scheme Liao....
Winson ( Date: 12-Aug-2013 09:40) Posted:
|
The 1QFY14 net profit of US$12.1m (-63% yoy) was significantly below expectations. Revenue declined 11% yoy to US$76.6m, while gross profits dropped 17%. The results were adversely affected by inventory drawdowns across its channels in China in view of looming price cuts, resulting in DES revenues declining 6% yoy. Licensing revenues from Japan were also down 33% yoy. Deutsche sees further erosion in royalty income in FY14, given continued competition in Japan, in particular, Abbott launched its Xience Xpedition in Japan in Jul. Expects further margin erosion due to, i) increasing costs in Japan, ii) integration of acquired business, and ii) increase sales and marketing costs. Deutsche lowers TP to $1 (from $1.15), based on 13x FY15e P/E. Maintains Hold rating. OCBC downgrades to Hold from buy, slashes TP to $0.96 from $1.60. Expects some near term selling pressure. CS cuts TP to $1.43 (from $1.80), but maintains Outperform rating. Nomura keeps at Buy with TP $1.80.
Any followers? I came out long ago and still don't find any interest to enter yet. Those who got it high can either do HIWTYL or buy and buy until it reaches the bottom, catching falling knives and needing alot of capital.
Tomique ( Date: 11-Aug-2013 14:19) Posted:
|
Lelong for this counter. Vomit blood day,
DrEaMzZz ( Date: 12-Aug-2013 09:02) Posted:
|
officially penny stock...
Drop so much today...
Why not use " heads I win, tails you lose" strategy?
Sell a little at a time, so that if it goes the wrong way (up) you still have stocks, maybe can make back some money if it climbs strongly.
If it continues to fall as you sell, then when it reaches your target price to buy back, then buy back and make sure you really buy back!!. This HIWTYL system is quite effective and can save you alot of nightmares and good for those who got stuck at higher prices.. Cheers. Hehe...
New123 ( Date: 08-Aug-2013 12:17) Posted:
|
down trend . Has to bounce up to $1.00 & above , if not better wait for the right direction?
Biotechnology company Biosensors’ (SGX: B20) reported an 11% decline in first-quarter sales to US$76.7m. Profits fell some 63% to US$12.1m.
The company’s main business activity lies in the manufacture of various types of drug-eluting stents (DES), which are medical device used to unclog blocked arteries. The company splits its revenue into four segments, namely, Critical Care, Interventional Cardiology, Cardiac Diagnostic and Licensing & Royalties.
Biosensor’s top-line decline was mainly due to a drop in revenues from Interventional Cardiology and Licensing & Royalties, both of which are the main revenue drivers for the company. The former made up 79% of the company’s total sales while the latter accounted for 17%.
Interventional Cardiology’s sales for the quarter slid 7.3% to US$60.9m from a year ago mainly due to a slowdown in DES sales in China. That in turn, was the result of the company’s intentional reduction in the inventory levels of distributors in China because of “on-going and upcoming tender activities.”
The company’s other DES markets in the Europe, Middle East & Africa (EMEA) and Asia Pacific regions all saw “strong, double-digit sales growth.”
Licensing & Royalties revenue, where Biosensors licenses its DES technology to others, was down by 32.7% to US$11.6m. Critical Care brought in US$3.43m in sales, up a smidgen from US$3.34m in the previous year.
Finally, Cardiac Diagnostic had US$706,000 in sales for the quarter. It is a new segment for Biosensors, and is the result of a consolidation of Spectrum Dynamics’ business. Spectrum Dynamics is a company that does cardiac imaging systems and was acquired by Biosensors for US$51m in May this year.
Biosensor’s CEO, Dr Jack Wang, had this to say regarding the acquisition: “The integration process of our recently acquired business, [Spectrum Dynamics], is well on track. We are excited about the recent Japanese regulatory approval of its D-SPECT system and we remain confident of our ability to unlock the potential of this business.”
The company’s profits fell proportionately more than the decline in revenues which suggests a compression in net profit margins. There are three reasons for this.
Firstly, gross margins fell from 85% to 79%. Biosensors had entered into an agreement with Terumo Corporation in Japan to distribute Nobori DES last year and the distribution activity this quarter was one of the reasons for the fall in gross margins.
The consolidation of Spectrum Dyanmics’ businesses also ate into Biosensor’s gross profits as Cardiac Diagnostics carry inherently lower margins.
Secondly, Biosensor had spent US$26.6m on sales & marketing expenses for the quarter, an increase of 19.3% from a year ago.
Finally, there was a 121% year-on-year increase in interest expenses to US$3.4m. The increase was mainly due to US$240m worth of debt that Biosensors issued on Jan 2013. Those loans are due for repayment after four years and carry an interest rate of 4.875% per year.
The three reasons were the main causes for Biosensor’s lower net profit margins.
Biosensors’ balance sheet remains robust with a total debt load of US$273m and a cash hoard worth US$546m. The company is satisfied with the amount of cash on hand and with “continued improvement in [its] operating performance” in the horizon, there are no plans currently for future fund raising activities.
The company has forecast a 15% year-on-year growth in revenues for the year. It expects sales continuing to climb in the EMEA and Asia Pacific regions and it is confident that DES sales in China will pick up in rest of the year. In addition, Biosensors also expects the Spectrum Dynamics acquisition to provide new markets for the company.
Shares of Biosensors closed at S$0.975 on Wednesday, which represents a trailing price-to-earnings ratio of 14 and a dividend yield of 2.6% based on last year’s full-year pay-out.
The company’s main business activity lies in the manufacture of various types of drug-eluting stents (DES), which are medical device used to unclog blocked arteries. The company splits its revenue into four segments, namely, Critical Care, Interventional Cardiology, Cardiac Diagnostic and Licensing & Royalties.
Biosensor’s top-line decline was mainly due to a drop in revenues from Interventional Cardiology and Licensing & Royalties, both of which are the main revenue drivers for the company. The former made up 79% of the company’s total sales while the latter accounted for 17%.
Interventional Cardiology’s sales for the quarter slid 7.3% to US$60.9m from a year ago mainly due to a slowdown in DES sales in China. That in turn, was the result of the company’s intentional reduction in the inventory levels of distributors in China because of “on-going and upcoming tender activities.”
The company’s other DES markets in the Europe, Middle East & Africa (EMEA) and Asia Pacific regions all saw “strong, double-digit sales growth.”
Licensing & Royalties revenue, where Biosensors licenses its DES technology to others, was down by 32.7% to US$11.6m. Critical Care brought in US$3.43m in sales, up a smidgen from US$3.34m in the previous year.
Finally, Cardiac Diagnostic had US$706,000 in sales for the quarter. It is a new segment for Biosensors, and is the result of a consolidation of Spectrum Dynamics’ business. Spectrum Dynamics is a company that does cardiac imaging systems and was acquired by Biosensors for US$51m in May this year.
Biosensor’s CEO, Dr Jack Wang, had this to say regarding the acquisition: “The integration process of our recently acquired business, [Spectrum Dynamics], is well on track. We are excited about the recent Japanese regulatory approval of its D-SPECT system and we remain confident of our ability to unlock the potential of this business.”
The company’s profits fell proportionately more than the decline in revenues which suggests a compression in net profit margins. There are three reasons for this.
Firstly, gross margins fell from 85% to 79%. Biosensors had entered into an agreement with Terumo Corporation in Japan to distribute Nobori DES last year and the distribution activity this quarter was one of the reasons for the fall in gross margins.
The consolidation of Spectrum Dyanmics’ businesses also ate into Biosensor’s gross profits as Cardiac Diagnostics carry inherently lower margins.
Secondly, Biosensor had spent US$26.6m on sales & marketing expenses for the quarter, an increase of 19.3% from a year ago.
Finally, there was a 121% year-on-year increase in interest expenses to US$3.4m. The increase was mainly due to US$240m worth of debt that Biosensors issued on Jan 2013. Those loans are due for repayment after four years and carry an interest rate of 4.875% per year.
The three reasons were the main causes for Biosensor’s lower net profit margins.
Biosensors’ balance sheet remains robust with a total debt load of US$273m and a cash hoard worth US$546m. The company is satisfied with the amount of cash on hand and with “continued improvement in [its] operating performance” in the horizon, there are no plans currently for future fund raising activities.
The company has forecast a 15% year-on-year growth in revenues for the year. It expects sales continuing to climb in the EMEA and Asia Pacific regions and it is confident that DES sales in China will pick up in rest of the year. In addition, Biosensors also expects the Spectrum Dynamics acquisition to provide new markets for the company.
Shares of Biosensors closed at S$0.975 on Wednesday, which represents a trailing price-to-earnings ratio of 14 and a dividend yield of 2.6% based on last year’s full-year pay-out.
MEDICAL device manufacturer Biosensors Group International announced a 63 per cent fall in net profit to US$12.1 million (S$15.3 million) for its first quarter ended June 30.
Lower profit was due to a combination of lower revenue, higher cost of sales and higher sales and marketing expenses.
Revenue was down 11 per cent to US$76.7 million.
The group is guiding for revenue for the fiscal year ending Mar 31, 2014, to grow by 15 per cent, driven by growth for drug-eluting stent sales and an expectation that China sales will recover.
Lower profit was due to a combination of lower revenue, higher cost of sales and higher sales and marketing expenses.
Revenue was down 11 per cent to US$76.7 million.
The group is guiding for revenue for the fiscal year ending Mar 31, 2014, to grow by 15 per cent, driven by growth for drug-eluting stent sales and an expectation that China sales will recover.
Boustead has Bionsensor bonds.......lol
just one day kenna burnt till both hand all bubble ready and still holding to it, hope monday will rebound.
May either rebound or drop next week. 0.96 must hold, if not
Management guidance of 15% revenue grow this year still intact. Share price may rebound in due course, believe worst is over?
Company will activate share buy back soon as it's already been approved. Be patient, don't kill yourself unnecessarily ok.
cycy818 ( Date: 07-Aug-2013 20:41) Posted:
|
omg. regret didn't listen to yiming2000 advice..... bleeding now.......
first thing to do on monday... cut lost.....
hope one day it would be a potential takeover target from big pharmaceutical companies.....
Will rebound next week due to stock oversold. Don't sell cheap to sortist. Keep for few quarters if you have holding power.
No company buy back. Bleed till no blood.
junction ( Date: 07-Aug-2013 18:41) Posted:
|
Financial results no good le ... can rebound ?